Weight Loss

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.

HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.

Adults with obstructive sleep apnea treated with CPAP for 24 weeks had improved vascular inflammation and lower unstable plaque volume, according to results published in Annals of the American Thoracic Society.

Clinics with vs. without Menopause Society Certified Practitioners were more likely to adhere to guidelines and not advertise compounded or bioidentical hormones, hormones for youthful appearance or weight loss or recommend hormone testing.

The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.

Obesity accounts for much of the risk for primary hypertension, and a treatment plan that could address both issues could substantially reduce a person’s underlying risk for cardiovascular disease and other complications.

Both obesity pharmacotherapy and bariatric surgery offer paths to substantial weight loss for people who struggle with excess weight, and new data suggest there is also an additional bonus benefit for many — a sustained reduction in blood pressure.